Skip to main content

Animations

MJFF Publications

5831 - 5840 of 6420 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • Summary Details
    OPEN
    Title: Mitochondrial haplogroups and cognitive progression in Parkinson’s disease
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1093/brain/awac327
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Evaluation of Compensation Strategies for Gait Impairment in Patients With Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000201159
    Citation Count: 14
  • Summary Details
    OPEN
    Title: A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice
    Journal Name: eLife
    Publisher: eLife Sciences Publications, Ltd
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.7554/elife.81453
    Citation Count: 54
  • Summary Details
    OPEN
    Title: Quality of Life for Patients With Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000200741
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Planning for Prevention of Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000200789
    Citation Count: 22
  • Summary Details
    OPEN
    Title: The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903316.50895.83
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903320.23411.f9
    Citation Count: 3
  • Summary Details
    OPEN
    Title: What Is the Role of Dopamine Transporter Imaging in Parkinson Prevention Clinical Trials?
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000200786
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Lifestyle Interventions for the Prevention of Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000200787
    Citation Count: 44
  • Summary Details
    OPEN
    Title: An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders Treated With Anti-CD20 Therapies
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903428.98962.0a
    Citation Count: 1
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.